{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:38:35Z","timestamp":1753893515178,"version":"3.41.2"},"reference-count":47,"publisher":"American Association for the Advancement of Science (AAAS)","funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L234038"],"award-info":[{"award-number":["L234038"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274015"],"award-info":[{"award-number":["82274015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Health Data Sci"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n            <jats:bold>Background:<\/jats:bold>\n            Since the launch of drug regulatory reform in 2015, China has substantially increased the availability of new cancer therapies. However, the efficacy evidence criteria for modified new anticancer drugs have not been evaluated. This cross-sectional study aimed to assess the pivotal trials supporting the indication approvals of innovative and modified new chemical anticancer drugs in China.\n            <jats:bold>Methods:<\/jats:bold>\n            The characteristics of indications, regulatory aspects, and pivotal trial designs were extracted and described. The primary efficacy endpoints of the pivotal clinical trials, including overall survival (OS) and progression-free survival (PFS), were quantitatively assessed by meta-analysis.\n            <jats:bold>Results:<\/jats:bold>\n            Between 2016 and 2022, 77 cancer therapeutics for 107 indications were approved in China based on 128 pivotal trials. Among the 107 indications, 64 (59.8%) were classified as innovative anticancer drugs, and 43 (40.2%) as modified new anticancer drugs. The study found that pivotal trials for innovative approvals tended to be single-arm trials, while modified approvals were more likely to employ randomized clinical trials with larger sample sizes and rigorous designs. Despite innovative drugs often receiving more expedited regulatory designations, there were no statistically significant differences in clinical benefit of OS or PFS outcomes between innovative and modified approvals.\n            <jats:bold>Conclusions:<\/jats:bold>\n            These results suggest that the current regulatory framework may prioritize the speed of approval for innovative drugs over the strength of supporting evidence. These findings align with the strategic trends of pharmaceutical companies and regulatory inclinations that aim to expedite the approval of innovative anticancer drugs with a high unmet need, thereby accelerating patients\u2019 accessibility to treatment.\n          <\/jats:p>","DOI":"10.34133\/hds.0263","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T16:09:33Z","timestamp":1741795773000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Assessment of Pivotal Trials Supporting the Indication Approvals of Innovative and Modified New Anticancer Drugs in China, 2016\u20132022"],"prefix":"10.34133","volume":"5","author":[{"given":"Lixia","family":"Fu","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology, \rPeking University First Hospital, Beijing, China."},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifen","family":"Xue","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, \rPeking University First Hospital, Beijing, China."},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, \rPeking University First Hospital, Beijing, China."},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoshu","family":"Jia","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, \rPeking University First Hospital, Beijing, China."},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Beijing, China."},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, \rPeking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Beijing, China."},{"name":"Department of Pharmacy, \rPeking University First Hospital, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, \rPeking University First Hospital, Beijing, China."},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs, Beijing, China."},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, \rPeking University, Beijing, China."},{"name":"State Key Laboratory of Natural and Biomimetic Drugs, \rSchool of Pharmaceutical Sciences, Peking University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"11","key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrd.2016.200","article-title":"Innovative drug availability in China","volume":"15","author":"Shao L","year":"2016","unstructured":"Shao L, Xu L, Li Q, Chakravarthy R, Yang Z, Kaitin KI. Innovative drug availability in China. Nat Rev Drug Discov. 2016;15(11):739\u2013740.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpt.2755","article-title":"Assessment of the delay in novel anticancer drugs between China and the United States: A comparative study of drugs approved between 2010 and 2021","volume":"113","author":"Luo X","year":"2023","unstructured":"Luo X, Du X, Li Z, Qian F, Yang Y. Assessment of the delay in novel anticancer drugs between China and the United States: A comparative study of drugs approved between 2010 and 2021. Clin Pharmacol Ther. 2023;113(1):170\u2013181.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","article-title":"Evolution of drug regulations and regulatory innovation for anticancer drugs in China","volume":"12","author":"Liu Y","year":"2022","unstructured":"Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, Fan Y, Ren L, Yin C, Yang H, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365\u20134377.","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nrd.2018.150","article-title":"Reforming China\u2019s drug regulatory system","volume":"17","author":"Xu L","year":"2018","unstructured":"Xu L, Gao H, Kaitin KI, Shao L. Reforming China\u2019s drug regulatory system. Nat Rev Drug Discov. 2018;17(12):858\u2013859.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_6_2","unstructured":"China Food and Drug Administration. Work plan for the reform of chemical drug registration classification. 2016. [accessed 26 Oct 2023] https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20160309151801706.html"},{"key":"e_1_3_4_7_2","unstructured":"Provisions for drug registration. 2020. [accessed 26 Oct 2023] http:\/\/english.nmpa.gov.cn\/2022-06\/30\/c_785628.htm"},{"key":"e_1_3_4_8_2","unstructured":"NMPA issues requirements for registration classification and application dossiers of chemical drugs. 2020.[accessed 26 Oct 2023] http:\/\/english.nmpa.gov.cn\/2020-06\/30\/c_528659.htm"},{"issue":"2","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s43441-022-00472-3","article-title":"Trends and Characteristics of New Drug Approvals in China, 2011\u20132021","volume":"57","author":"Su L","year":"2023","unstructured":"Su L, Liu S, Li G, Xie C, Yang H, Liu Y, Yin C, Chen X. Trends and Characteristics of New Drug Approvals in China, 2011\u20132021. Ther Innov Regul Sci. 2023;57(2):343\u2013351.","journal-title":"Ther Innov Regul Sci"},{"issue":"10","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/d41573-022-00077-3","article-title":"Trends in innovative drug development in China","volume":"21","author":"Su X","year":"2022","unstructured":"Su X, Wang H, Zhao N, Wang T, Cui Y. Trends in innovative drug development in China. Nat Rev Drug Discov. 2022;21(10):709\u2013710.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","article-title":"Evolution of innovative drug R&D in China","volume":"21","author":"Li G","year":"2022","unstructured":"Li G, Liu Y, Hu H, Yuan S, Zhou L, Chen X. Evolution of innovative drug R&D in China. Nat Rev Drug Discov. 2022;21(8):553\u2013554.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China","volume":"20","author":"Li G","year":"2021","unstructured":"Li G, Liu Y, Xie C, Zhou Q, Chen X. Characteristics of expedited programmes for cancer drug approval in China. Nat Rev Drug Discov. 2021;20(6):416.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"e2225973","DOI":"10.1001\/jamanetworkopen.2022.25973","article-title":"Overall survival benefits of cancer drugs approved in China from 2005 to 2020","volume":"5","author":"Zhang YC","year":"2022","unstructured":"Zhang YC, Naci H, Wagner AK, Xu ZY, Yang Y, Zhu J, Ji JF, Shi LW, Guan XD. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw Open. 2022;5(8):e2225973.","journal-title":"JAMA Netw Open"},{"issue":"15","key":"e_1_3_4_14_2","first-page":"1523","article-title":"Analysis and thinking on the application and approval of improved new chemical drugs in China","volume":"32","author":"Lv Y","year":"2023","unstructured":"Lv Y, Zhang YM, Mao NY. Analysis and thinking on the application and approval of improved new chemical drugs in China. Chin J New Drugs. 2023;32(15):1523\u20131530.","journal-title":"Chin J New Drugs"},{"issue":"5","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","article-title":"Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland","volume":"20","author":"Michaeli DT","year":"2022","unstructured":"Michaeli DT, Mills M, Kanavos P. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ. Health Policy. 2022;20(5):757\u2013768.","journal-title":"Appl Health Econ. Health Policy"},{"issue":"3","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"e0173451","DOI":"10.1371\/journal.pone.0173451","article-title":"Assessment of potential factors associating with costs of hospitalizing cardiovascular diseases in 141 hospitals in Guangxi, China","volume":"12","author":"Hu C","year":"2017","unstructured":"Hu C, Zhou L-F, Zhang M-X, Kong L-Q, Liu J-J, Feng Q-M, Lu W, Wei B, Zhao LP. Assessment of potential factors associating with costs of hospitalizing cardiovascular diseases in 141 hospitals in Guangxi, China. PLOS ONE. 2017;12(3):e0173451.","journal-title":"PLOS ONE"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"997694","DOI":"10.3389\/fpubh.2022.997694","article-title":"Catastrophic health expenditure, incidence, trend and socioeconomic risk factors in China: A systematic review and meta-analysis","volume":"10","author":"Zhang F","year":"2023","unstructured":"Zhang F, Jiang J, Yang M, Zou K, Chen D. Catastrophic health expenditure, incidence, trend and socioeconomic risk factors in China: A systematic review and meta-analysis. Front Public Health. 2023;10:997694.","journal-title":"Front Public Health"},{"issue":"11","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"e31371","DOI":"10.1016\/j.heliyon.2024.e31371","article-title":"Real-world drug treatment models of novel targeted drugs in Chinese patients with gynecological cancer from 2017 to 2021: A cross-sectional analysis","volume":"10","author":"Li C","year":"2024","unstructured":"Li C, Jin J, Tang J. Real-world drug treatment models of novel targeted drugs in Chinese patients with gynecological cancer from 2017 to 2021: A cross-sectional analysis. Heliyon. 2024;10(11):e31371.","journal-title":"Heliyon"},{"issue":"7","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-022-01161-7","article-title":"Prices and clinical benefit of national price-negotiated anticancer medicines in China","volume":"40","author":"Zhang YC","year":"2022","unstructured":"Zhang YC, Wei YX, Li HQY, Chen YX, Guo YR, Han S, Shi LW, Guan XD. Prices and clinical benefit of national price-negotiated anticancer medicines in China. Pharmacoeconomics. 2022;40(7):715\u2013724.","journal-title":"Pharmacoeconomics"},{"issue":"35","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021","volume":"40","author":"Michaeli DT","year":"2022","unstructured":"Michaeli DT, Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;40(35):4095\u20134106.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_21_2","first-page":"101088","article-title":"List prices and clinical value of anticancer drugs in China, Japan, and South Korea: A retrospective comparative study","volume":"47","author":"Pan J","year":"2024","unstructured":"Pan J, Wei X, Lu H, Wu X, Li C, Hai X, Lan T, Dong Q, Yang Y, Jakovljevic M, et al. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: A retrospective comparative study. Lancet Reg Health West Pac. 2024;47:101088.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004332","article-title":"Price negotiation and pricing of anticancer drugs in China: An observational study","volume":"21","author":"Zhou J","year":"2024","unstructured":"Zhou J, Lan T, Lu H, Pan J. Price negotiation and pricing of anticancer drugs in China: An observational study. PLOS Med. 2024;21(1): Article e1004332.","journal-title":"PLOS Med"},{"key":"e_1_3_4_23_2","first-page":"8150","article-title":"Association of launch price and clinical value with reimbursement decisions for anticancer drugs in China","volume":"12","author":"Zhou J","year":"2024","unstructured":"Zhou J, Lu H, Pan J. Association of launch price and clinical value with reimbursement decisions for anticancer drugs in China. Int J Health Policy Manag. 2024;12:8150.","journal-title":"Int J Health Policy Manag"},{"issue":"5","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: A cost-benefit analysis","volume":"21","author":"Vokinger KN","year":"2020","unstructured":"Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, Kesselheim AS. Prices and clinical benefit of cancer drugs in the USA and Europe: A cost-benefit analysis. Lancet Oncol. 2020;21(5):664\u2013670.","journal-title":"Lancet Oncol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"113042","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega SE","year":"2020","unstructured":"Salas-Vega SE, Shearer E, Mossialos E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc Sci Med. 2020;258:113042.","journal-title":"Soc Sci Med"},{"issue":"9","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, Clinical benefit, and policy implications in the US and Europe","volume":"7","author":"Vokinger KN","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Analysis of launch and postapproval cancer drug pricing, Clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 2021;7(9): Article e212026.","journal-title":"JAMA Oncol"},{"issue":"2","key":"e_1_3_4_27_2","first-page":"179","article-title":"Study on value-based medical insurance access and pricing methods of multi-indication drugs","volume":"34","author":"Yingcheng W","year":"2023","unstructured":"Yingcheng W, Yao W, Lan Y, Mingjun R, Hongchao L. Study on value-based medical insurance access and pricing methods of multi-indication drugs. China Pharm. 2023;34(2):179\u2013184.","journal-title":"China Pharm"},{"issue":"4","key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10637-022-01227-5","article-title":"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA","volume":"40","author":"Michaeli DT","year":"2022","unstructured":"Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Invest New Drugs. 2022;40(4):798\u2013809.","journal-title":"Invest New Drugs"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h4679","article-title":"Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: Systematic review","volume":"351","author":"Wang B","year":"2015","unstructured":"Wang B, Kesselheim AS. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: Systematic review. BMJ. 2015;351: Article h4679.","journal-title":"BMJ"},{"issue":"6","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13224","article-title":"Characteristics of clinical studies used for US Food and Drug Administration supplemental indication approvals of drugs and biologics, 2017 to 2019","volume":"4","author":"Dhodapkar M","year":"2021","unstructured":"Dhodapkar M, Zhang AD, Puthumana J, Downing NS, Shah ND, Ross JS. Characteristics of clinical studies used for US Food and Drug Administration supplemental indication approvals of drugs and biologics, 2017 to 2019. JAMA Netw Open. 2021;4(6): Article e2113224.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"e_1_3_4_31_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103578","article-title":"Evaluation of clinical trial designs for novel anticancer drugs in China: A cohort study of drugs approved between 2015 and 2021","volume":"28","author":"Luo X","year":"2023","unstructured":"Luo X, Guo Q, Du X, Huang L, Chow S-C, Yang Y. Evaluation of clinical trial designs for novel anticancer drugs in China: A cohort study of drugs approved between 2015 and 2021. Drug Discov Today. 2023;28(6): Article 103578.","journal-title":"Drug Discov Today"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102177","article-title":"Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022","volume":"63","author":"Luo X","year":"2023","unstructured":"Luo X, Du X, Huang L, Guo Q, Lv X, Wang C, Liu H, Zhou Y, Xue X, Li Z, et al. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022. EClinicalMedicine. 2023;63: Article 102177.","journal-title":"EClinicalMedicine"},{"key":"e_1_3_4_33_2","unstructured":"Pharmacodia database. 2023. [accessed 26 Oct 2023] https:\/\/www.pharmacodia.com\/"},{"key":"e_1_3_4_34_2","unstructured":"Center For Drug Evaluation China Food and Drug Administration. The Center for Drug Evaluation launched the work of technical evaluation report and drug instruction information disclosure. 2016. [accessed 26 Oct 2023] https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/cb05e61ddadd0223a49620937238fbbf"},{"key":"e_1_3_4_35_2","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC\/DD Index 2023. 2023. [accessed 26 Oct 2023] https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"e_1_3_4_36_2","unstructured":"Center For Drug Evaluation NMPA. Launched drug information. 2016. [accessed 26 Oct 2023] https:\/\/www.cde.org.cn\/main\/xxgk\/listpage\/b40868b5e21c038a6aa8b4319d21b07d"},{"issue":"1","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/10781552221112015","article-title":"Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021","volume":"29","author":"Kandemir EA","year":"2022","unstructured":"Kandemir EA. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021. J Oncol Pharm Pract. 2022;29(1):191\u2013207.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/jnci\/djad212","article-title":"Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations","volume":"116","author":"Michaeli DT","year":"2024","unstructured":"Michaeli DT, Michaeli T, Albers S, Michaeli JC. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations. J Natl Cancer Inst. 2024;116(2):216\u2013229.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clinthera.2013.04.004","article-title":"Innovating by developing new uses of already-approved drugs: Trends in the marketing approval of supplemental indications","volume":"35","author":"DiMasi JA","year":"2013","unstructured":"DiMasi JA. Innovating by developing new uses of already-approved drugs: Trends in the marketing approval of supplemental indications. Clin Ther. 2013;35(6):808\u2013818.","journal-title":"Clin Ther"},{"issue":"4","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jamaoncol.2021.7230","article-title":"Characteristics of clinical trials evaluating biosimilars in the treatment of cancer","volume":"8","author":"Bloomfield D","year":"2022","unstructured":"Bloomfield D, D\u2019Andrea E, Nagar S, Kesselheim A. Characteristics of clinical trials evaluating biosimilars in the treatment of cancer. JAMA Oncol. 2022;8(4):537\u2013545.","journal-title":"JAMA Oncol"},{"issue":"4","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012","volume":"311","author":"Downing NS","year":"2014","unstructured":"Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. 2014;311(4):368.","journal-title":"JAMA"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3897\/pharmacia.69.e72548"},{"issue":"4","key":"e_1_3_4_43_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017","volume":"3","author":"Zhang AD","year":"2020","unstructured":"Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017. JAMA Netw Open. 2020;3(4): Article e203284.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.critrevonc.2015.10.018","article-title":"Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials","volume":"98","author":"Ghatalia P","year":"2016","unstructured":"Ghatalia P, Morgan CJ, Sonpavde G. Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Crit Rev Oncol Hematol. 2016;98:122\u2013136.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1200\/JCO.2017.77.1592","article-title":"Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines","volume":"36","author":"Hwang TJ","year":"2018","unstructured":"Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, Darrow JJ. Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines. J Clin Oncol. 2018;36(18):1805\u20131812.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12454","article-title":"Analysis of supportive evidence for US Food and Drug Administration approvals of novel drugs in 2020","volume":"5","author":"Mitra-Majumdar M","year":"2022","unstructured":"Mitra-Majumdar M, Gunter SJ, Kesselheim AS, Brown BL, Joyce KW, Ross M, Pham C, Avorn J, Darrow JJ. Analysis of supportive evidence for US Food and Drug Administration approvals of novel drugs in 2020. JAMA Netw Open. 2022;5(5): Article e2212454.","journal-title":"JAMA Netw Open"},{"issue":"18","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2017.5150","article-title":"Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010","volume":"317","author":"Downing NS","year":"2017","unstructured":"Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA. 2017;317(18):1854\u20131863.","journal-title":"JAMA"},{"issue":"6","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40264-017-0526-1","article-title":"Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals","volume":"40","author":"Schick A","year":"2017","unstructured":"Schick A, Miller KL, Lanthier M, Dal Pan G, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf. 2017;40(6):497\u2013503.","journal-title":"Drug Saf"}],"container-title":["Health Data Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/hds.0263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:33:51Z","timestamp":1746185631000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/hds.0263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":47,"alternative-id":["10.34133\/hds.0263"],"URL":"https:\/\/doi.org\/10.34133\/hds.0263","relation":{},"ISSN":["2765-8783"],"issn-type":[{"type":"electronic","value":"2765-8783"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0263"}}